What is HC Wainwright’s Estimate for TARS Q4 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at HC Wainwright issued their Q4 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst O. Livnat forecasts that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $73.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ FY2028 earnings at $5.10 EPS and FY2029 earnings at $6.29 EPS.

Several other equities research analysts also recently commented on TARS. The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Guggenheim restated a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday. Finally, Barclays lowered their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $61.33.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock opened at $42.56 on Thursday. The business has a 50-day simple moving average of $51.31 and a 200 day simple moving average of $43.00. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -11.17 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.08. The firm had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TARS. Crowley Wealth Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $25,000. GF Fund Management CO. LTD. bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $44,000. R Squared Ltd purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $53,000. FMR LLC increased its stake in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Quarry LP purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $166,000. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.